

## ASX ANNOUNCEMENT

29 May 2018

### **SPP offer closes oversubscribed Total proceeds raised under the SPP increased to A\$5 million**

Volpara Health Technologies Limited (**Volpara**) is pleased to announce the successful completion of its share purchase plan (**SPP**) offer to existing eligible shareholders (including retail shareholders), raising a total of A\$5 million.

The SPP was announced to the ASX on 7 May 2018 following the successful completion of Volpara's A\$15 million institutional share (**Placement**) at \$0.60 per share, which was also oversubscribed. The SPP allowed eligible shareholders the ability to subscribe for up to A\$15,000 of new fully paid ordinary shares in Volpara at the same price as the Placement, without paying any brokerage. The SPP closed at 5.00pm (Sydney time) on Friday, 25 May 2018.

The SPP closed with applications of more than A\$12.5 million, well in excess of the expected A\$3 million, as set out in the SPP Booklet. As a result of this, the board used its discretion under the terms and conditions of the SPP to increase the aggregate amount to be raised under the SPP offer to A\$5 million and then to scale back the allotment of shares to all applicants in excess of this amount on a pro rata basis. The new Volpara shares under the SPP will be issued at a price of A\$0.60 per share, being the price at which shares were issued under the Placement.

The funds raised under the Placement and SPP will be used to expand Volpara's sales force, particularly in the United States, for product enhancements to increase Volpara's revenue per woman screened, to move Asia-Pac into the commercialisation phase, and for general working capital purposes.

The new shares under the SPP will be issued to applicants on Thursday, 31 May 2018 and the new shares will rank equally with all existing Volpara fully paid ordinary shares on issue. Holding statements for the SPP shares will be despatched, and refunds of subscription monies due to the scale back will be made, on or around, Thursday, 31 May 2018.

The Board and Management thank participating shareholders for their support of the SPP and their ongoing support of Volpara as it continues its growth in key global markets.

For further information please contact:

**Ralph Highnam**  
Chief Executive Officer  
[ralph.highnam@volparasolutions.com](mailto:ralph.highnam@volparasolutions.com)  
+64 21 149 0541

#### **About Volpara Health Technologies Limited (ASX:VHT)**

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical applications for screening clinics provide real-time feedback on breast density, compression, dose and quality, while its enterprise-wide software, VolparaEnterprise, provides role-specific dashboards and wide-ranging benchmarking analytics to help clinics manage their business more efficiently.

VHT's technology and services have been used by customers and/or research projects in 36 countries and are supported by numerous patents, trademarks and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$40 million, including A\$20 million in April and May 2018. VHT is based in Wellington, New Zealand.

Further information about Volpara can be found at <https://volparasolutions.com>

#### **Not for release to US wire services**

*This announcement has been prepared for publication in Australia and may not be released or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 (as amended, the US Securities Act) and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration of the US Securities Act and applicable US state securities laws.*